Recently, Molinaro et al. discussed, that IDH -wild-type and IDH -mutant glioblastoma patients benefit from a maximized percentage of resection of contrast- and non-contrast enhancing tumor regardless the MGMT status [30]. The gene discussed is MGMT; the disease is neoplasm.